Blog

IR – Press Release 2017-04-03: Zynex Announces 2016 Year End Results

April 03, 2017

Zynex Announces 2016 Year End Results

LONE TREE, Colo., April 3, 2017 /PRNEWSWIRE/ — Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announces 2016 year-end financial results.

President and CEO Commentary:

Thomas Sandgaard, CEO commented: “2016 was an important period in our turn-around with growth in orders, revenue growth and a return to profitability. Orders grew 86% compared to the prior year and revenue grew 14% in 2016 to $13.3 million. Our fourth quarter 2016 showed net income of $209,000 and the full year net income was $69,000. A strong Gross Profit Margin of 74% combined with our SG&A being flat compared to the prior year was significant in returning to profit.

We continue to see a strong demand for our flagship product, the NexWave, less competition than in prior years and continued strong insurance reimbursement. Going forward we are looking to add more products to this product line and well as continuing to develop and expand our sales force.

Our Monitoring Solutions division is still working with the FDA on our Blood Volume Monitor, a product that can detect blood loss during surgery and internal bleeding during recovery. We believe there is a huge unmet need for monitoring patient fluid balance in hospital settings as well as other applications such as military use in battlefield hemorrhaging.

Subsequent to year end we closed a financing of $1 million on February 28, 2017 and we have used the proceeds to partially pay down on our line of credit and to fuel the production of product needed to keep up with sales orders and sales rep demonstration inventory. The balance on our line of credit at the end of March 2017 was $2.1 million, down $600,000 compared to the beginning of the year. We expect to see an immediate impact in sales order growth as a result of being able to keep up with sales orders. We should be able to estimate the financial impact for the year more accurately in the next few months as we learn more about the actual order growth.”

Summary of Financial Results:

The Company’s net revenue increased 14% to $13,313,000 for 2016, compared to $11,641,000 for the year ended December 31, 2015. The increase was primarily due to increase in orders as a result of hiring additional sales rep early in the year. Cost of Goods Sold decreased from $3,517,000 in 2016 compared to $4,937,000 in 2015 which reflects an increase in Gross Profit Margin to 74% versus 58% in 2015.

The Company reported Selling, General and Administrative (“SG&A”) expenses of $9,156,000 for 2016, compared to $9,185,000 for the year ended December 31, 2015. The Company’s SG&A expenses remained flat year over year while revenue increased, resulting in an improved operating result.

The Company reported net income of $69,000 or less than one cent per share for the full year of 2016 compared to a net loss of $2.9 million in 2015 or nine cents per share.

The Company’s cash and line of credit balance as of December 31, 2016 was $247,000 and $2,771,000, respectively, as compared to cash and line of credit balance as of December 31, 2015 of $8,000 and $4,002,000.

Webcast Details: Monday, April 3, 2017 at 9:00 a.m. MT – 11:00 a.m. ET

To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:
https://www.webcaster4.com/Webcast/Page/1487/20429

US PARTICIPANT DIAL IN (TOLL FREE):
1-844-825-9790
INTERNATIONAL DIAL IN:
1-412-317-5170
Canada Toll Free:
1-855-669-9657

 

 

 

 

ZYNEX, INC.

CONSOLIDATED BALANCE SHEET
(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)
 
    December 31,
2016
    December 31,
2015
 
ASSETS                
Current Assets:                
Cash   $ 247     $ 8  
Accounts receivable, net     3,028       2,426  
Inventory, net     107       305  
Prepaid expenses     40       27  
Income tax receivable            
Total current assets     3,422       2,766  
Property and equipment, net     580       801  
Deposits     55       55  
Intangible assets, net     34       74  
Total assets   $ 4,091     $ 3,696  
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY                
Current Liabilities:                
Line of credit   $ 2,771     $ 4,002  
Current portion of capital leases     118       109  
Accounts payable     2,879       2,477  
Deferred revenue     54       89  
Deferred insurance reimbursement     880          
Income taxes payable     79       79  
Accrued payroll and payroll taxes     732       484  
Other accrued liabilities     232       299  
Total current liabilities     7,745       7,539  
Capitalized leases, less current portion     136       216  
Warranty liability     12       12  
Total liabilities     7,893       7,767  
Stockholders’ (Deficit) Equity:                
Preferred stock; $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding            
Common stock, $.001 par value, 100,000,000 shares authorized, 31,271,234 shares issued and outstanding     31       31  
Paid-in capital     6,032       5,832  
Accumulated deficit     (9,776 )     (9,845 )
Total Zynex, Inc. stockholders’ deficit     (3,713 )     (3,982 )
Non-controlling interest     (89 )     (89 )
Total Stockholders’ deficit     (3,802 )     (4,071 )
    $ 4,091     $ 3,696  

 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS

(AMOUNTS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

YEARS ENDED DECEMBER 31

 

    2016     2015  
Net revenue:                
Rental   $ 4,409     $ 2,480  
Product and supply     8,886       7,989  
Pharmacy and other     18       1,172  
      13,313       11,641  
Operating Expenses                
Cost of revenue – rental, product and supply     (3,517 )     (4,937 )
Selling, general and administrative expenses     (9,156 )     (9,185 )
                 
                 
Loss from operations     640       (2,481 )
Other income (expense):                
Interest expense     (352 )     (503 )
Other income (expense)     (204 )     (7 )
      (556 )     (510 )
Loss before income taxes     84       (2,991 )
Income tax benefit (expense)     (15 )     57  
Net income (loss)     69       (2,934 )
Plus: Net loss – non-controlling interest           23  
Net income (loss) – attributable to Zynex, Inc.   $ 69     $ (2,911 )
Net loss per share – attributable to Zynex, Inc.:                
Basic   $ 0.00     $ (0.09 )
Diluted   $ 0.00     $ (0.09 )
Weighted average number of common shares outstanding:                
Basic     31,271,234       31,271,234  
Diluted     31,271,234       31,271,234  

 

 

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN THOUSANDS)
YEARS ENDED DECEMBER 31

 

    2016     2015  
Cash flows from operating activities:                
Net income (loss)   $ 69     $ (2,934 )
Adjustments to reconcile net loss to net cash provided (used) in operating activities:                
Depreciation expense     395       367  
Noncore inventory write-off            
Write-off rental units            
Net gain on lease termination            
Provision for losses on accounts receivable     485       1,040  
Amortization of intangible assets     40       57  
Amortization of financing fees            
Issuance of common stock for services            
Provision for obsolete inventory           28  
Deferred rent            
Employee stock-based compensation expense     200       130  
Changes in operating assets and liabilities:                
Accounts receivable     (1087 )     (277 )
Inventory     198       1,602  
Prepaid expenses     (14 )     223  
Income tax receivable           268  
Deposits and other current assets           (53 )
Deferred revenue     845       (23 )
Accounts payable     402       (67 )
Accrued liabilities     167       (20 )
Income taxes payable            
Net cash provided by operating activities     1,700       341  
Cash flows from investing activities:                
Net disposals (purchases) of equipment           9  
Change in inventory used for rental     (174 )     99  
Payments on contingent consideration            
Net cash provided by investing activities     (174 )     108  
Cash flows from financing activities:                
Net repayments on line of credit     (1,232 )     (440 )
Proceeds from notes payable and capital leases            
Payments on notes payable and capital lease obligations     (72 )     (60 )
Net cash used in financing activities     (1,304 )     (504 )
Net decrease in cash     239       (55 )
Cash at the beginning of the period     8       63  
Cash at the end of the period   $ 247     $ 8  
Supplemental cash flow information:                
Interest paid   $ 351     $ 503  
Income taxes paid (including interest and penalties)            
Supplemental disclosure of non-cash investing and financing activities:                
Deposit used to purchase leasehold improvements   $     $  

 

 

 

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016.

Contact:
Zynex, Inc.
(303) 703-4906

SOURCE Zynex

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/zynex-announces-2016-year-end-results-300433406.html

Copyright (C) 2017 PR Newswire. All rights reserved


0